Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carpronium chloride is a synthetic quaternary ammonium compound and a direct-acting muscarinic acetylcholine receptor agonist. Originally developed in Japan by Daiichi Pharmaceutical, it is primarily used as a topical hair growth stimulant to treat various forms of alopecia, including alopecia areata and androgenetic alopecia, as well as vitiligo vulgaris and seborrhea sicca. By mimicking parasympathetic activity, carpronium chloride dilates local capillaries and enhances blood circulation in the scalp, thereby improving nutrient and oxygen delivery to hair follicles and promoting hair regrowth. It is marketed in Japan under brand names such as Furozin and the over-the-counter Caloyan series. An oral formulation was historically marketed under the brand name Actinamin for the treatment of gastroptosis, but has since been discontinued.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carpronium chloride.